The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant Vaccines-Global Market Insights and Sales Trends 2025
Synopsis
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
The global Recombinant Vaccines market size is expected to reach US$ 17170 million by 2029, growing at a CAGR of 11.0% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Vaccines in various end use industries. The expanding demands from the Recombinant Human Vaccines and Animal Recombinant Vaccines, are propelling Recombinant Vaccines market. Subunit Recombinant Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Vaccines covered in this report include Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG and Bharat Biotech, etc.
The global Recombinant Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
AstraZeneca Plc.
Johnson & Johnson
Emergent BioSolutions Inc
Novavax, Inc
Serum Institute of India Pvt. Ltd
Dynavax Technologies Corporation
Global Recombinant Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Vaccines market, Segment by Type:
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Global Recombinant Vaccines market, by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
The global Recombinant Vaccines market size is expected to reach US$ 17170 million by 2029, growing at a CAGR of 11.0% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Vaccines in various end use industries. The expanding demands from the Recombinant Human Vaccines and Animal Recombinant Vaccines, are propelling Recombinant Vaccines market. Subunit Recombinant Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Vaccines covered in this report include Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG and Bharat Biotech, etc.
The global Recombinant Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck & Co., Inc
Green Cross Corporation
Pfizer Inc.
Bayer AG
Sanofi S A.
Protein Science Corporation
GlaxoSmithKline Plc.
Novartis AG
Bharat Biotech
AstraZeneca Plc.
Johnson & Johnson
Emergent BioSolutions Inc
Novavax, Inc
Serum Institute of India Pvt. Ltd
Dynavax Technologies Corporation
Global Recombinant Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Vaccines market, Segment by Type:
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Global Recombinant Vaccines market, by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Recombinant Vaccines
1.1 Recombinant Vaccines Market Overview
1.1.1 Recombinant Vaccines Product Scope
1.1.2 Recombinant Vaccines Market Status and Outlook
1.2 Global Recombinant Vaccines Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Recombinant Vaccines Market Size by Region (2018-2029)
1.4 Global Recombinant Vaccines Historic Market Size by Region (2018-2023)
1.5 Global Recombinant Vaccines Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Recombinant Vaccines Market Size (2018-2029)
1.6.1 North America Recombinant Vaccines Market Size (2018-2029)
1.6.2 Europe Recombinant Vaccines Market Size (2018-2029)
1.6.3 Asia-Pacific Recombinant Vaccines Market Size (2018-2029)
1.6.4 Latin America Recombinant Vaccines Market Size (2018-2029)
1.6.5 Middle East & Africa Recombinant Vaccines Market Size (2018-2029)
2 Recombinant Vaccines Market by Type
2.1 Introduction
2.1.1 Subunit Recombinant Vaccines
2.1.2 Attenuated Recombinant Vaccines
2.1.3 Vector Recombinant Vaccines
2.2 Global Recombinant Vaccines Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Recombinant Vaccines Historic Market Size by Type (2018-2023)
2.2.2 Global Recombinant Vaccines Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Recombinant Vaccines Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Recombinant Vaccines Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Recombinant Vaccines Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Recombinant Vaccines Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Recombinant Vaccines Revenue Breakdown by Type (2018-2029)
3 Recombinant Vaccines Market Overview by Application
3.1 Introduction
3.1.1 Recombinant Human Vaccines
3.1.2 Animal Recombinant Vaccines
3.2 Global Recombinant Vaccines Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Recombinant Vaccines Historic Market Size by Application (2018-2023)
3.2.2 Global Recombinant Vaccines Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Recombinant Vaccines Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Recombinant Vaccines Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Recombinant Vaccines Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Recombinant Vaccines Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Recombinant Vaccines Revenue Breakdown by Application (2018-2029)
4 Recombinant Vaccines Competition Analysis by Players
4.1 Global Recombinant Vaccines Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2022)
4.3 Date of Key Players Enter into Recombinant Vaccines Market
4.4 Global Top Players Recombinant Vaccines Headquarters and Area Served
4.5 Key Players Recombinant Vaccines Product Solution and Service
4.6 Competitive Status
4.6.1 Recombinant Vaccines Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck & Co., Inc
5.1.1 Merck & Co., Inc Profile
5.1.2 Merck & Co., Inc Main Business
5.1.3 Merck & Co., Inc Recombinant Vaccines Products, Services and Solutions
5.1.4 Merck & Co., Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.1.5 Merck & Co., Inc Recent Developments
5.2 Green Cross Corporation
5.2.1 Green Cross Corporation Profile
5.2.2 Green Cross Corporation Main Business
5.2.3 Green Cross Corporation Recombinant Vaccines Products, Services and Solutions
5.2.4 Green Cross Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.2.5 Green Cross Corporation Recent Developments
5.3 Pfizer Inc.
5.3.1 Pfizer Inc. Profile
5.3.2 Pfizer Inc. Main Business
5.3.3 Pfizer Inc. Recombinant Vaccines Products, Services and Solutions
5.3.4 Pfizer Inc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer AG Recent Developments
5.4 Bayer AG
5.4.1 Bayer AG Profile
5.4.2 Bayer AG Main Business
5.4.3 Bayer AG Recombinant Vaccines Products, Services and Solutions
5.4.4 Bayer AG Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer AG Recent Developments
5.5 Sanofi S A.
5.5.1 Sanofi S A. Profile
5.5.2 Sanofi S A. Main Business
5.5.3 Sanofi S A. Recombinant Vaccines Products, Services and Solutions
5.5.4 Sanofi S A. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi S A. Recent Developments
5.6 Protein Science Corporation
5.6.1 Protein Science Corporation Profile
5.6.2 Protein Science Corporation Main Business
5.6.3 Protein Science Corporation Recombinant Vaccines Products, Services and Solutions
5.6.4 Protein Science Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.6.5 Protein Science Corporation Recent Developments
5.7 GlaxoSmithKline Plc.
5.7.1 GlaxoSmithKline Plc. Profile
5.7.2 GlaxoSmithKline Plc. Main Business
5.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Products, Services and Solutions
5.7.4 GlaxoSmithKline Plc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.7.5 GlaxoSmithKline Plc. Recent Developments
5.8 Novartis AG
5.8.1 Novartis AG Profile
5.8.2 Novartis AG Main Business
5.8.3 Novartis AG Recombinant Vaccines Products, Services and Solutions
5.8.4 Novartis AG Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis AG Recent Developments
5.9 Bharat Biotech
5.9.1 Bharat Biotech Profile
5.9.2 Bharat Biotech Main Business
5.9.3 Bharat Biotech Recombinant Vaccines Products, Services and Solutions
5.9.4 Bharat Biotech Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.9.5 Bharat Biotech Recent Developments
5.10 AstraZeneca Plc.
5.10.1 AstraZeneca Plc. Profile
5.10.2 AstraZeneca Plc. Main Business
5.10.3 AstraZeneca Plc. Recombinant Vaccines Products, Services and Solutions
5.10.4 AstraZeneca Plc. Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.10.5 AstraZeneca Plc. Recent Developments
5.11 Johnson & Johnson
5.11.1 Johnson & Johnson Profile
5.11.2 Johnson & Johnson Main Business
5.11.3 Johnson & Johnson Recombinant Vaccines Products, Services and Solutions
5.11.4 Johnson & Johnson Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.11.5 Johnson & Johnson Recent Developments
5.12 Emergent BioSolutions Inc
5.12.1 Emergent BioSolutions Inc Profile
5.12.2 Emergent BioSolutions Inc Main Business
5.12.3 Emergent BioSolutions Inc Recombinant Vaccines Products, Services and Solutions
5.12.4 Emergent BioSolutions Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.12.5 Emergent BioSolutions Inc Recent Developments
5.13 Novavax, Inc
5.13.1 Novavax, Inc Profile
5.13.2 Novavax, Inc Main Business
5.13.3 Novavax, Inc Recombinant Vaccines Products, Services and Solutions
5.13.4 Novavax, Inc Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.13.5 Novavax, Inc Recent Developments
5.14 Serum Institute of India Pvt. Ltd
5.14.1 Serum Institute of India Pvt. Ltd Profile
5.14.2 Serum Institute of India Pvt. Ltd Main Business
5.14.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Products, Services and Solutions
5.14.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.14.5 Serum Institute of India Pvt. Ltd Recent Developments
5.15 Dynavax Technologies Corporation
5.15.1 Dynavax Technologies Corporation Profile
5.15.2 Dynavax Technologies Corporation Main Business
5.15.3 Dynavax Technologies Corporation Recombinant Vaccines Products, Services and Solutions
5.15.4 Dynavax Technologies Corporation Recombinant Vaccines Revenue (US$ Million) & (2018-2023)
5.15.5 Dynavax Technologies Corporation Recent Developments
6 North America
6.1 North America Recombinant Vaccines Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Recombinant Vaccines Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Vaccines Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Recombinant Vaccines Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Vaccines Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Recombinant Vaccines Market Dynamics
11.1 Recombinant Vaccines Industry Trends
11.2 Recombinant Vaccines Market Drivers
11.3 Recombinant Vaccines Market Challenges
11.4 Recombinant Vaccines Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
